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Abstract
Background: The incorporation of diagnostic and therapeutic improvements, as well as the
different smoking patterns, may have had an influence on the observed variability in renal cancer
mortality across Europe. This study examined time trends in kidney cancer mortality in fourteen
European countries during the last two decades of the 20th century.
Methods: Kidney cancer deaths and population estimates for each country during the period
1981–2000 were drawn from the World Health Organization Mortality Database. Age- and period-
adjusted mortality rates, as well as annual percentage changes in age-adjusted mortality rates, were
calculated for each country and geographical region. Log-linear Poisson models were also fitted to
study the effect of age, death period, and birth cohort on kidney cancer mortality rates within each
country.
Results: For men, the overall standardized kidney cancer mortality rates in the eastern, western,
and northern European countries were 20, 25, and 53% higher than those for the southern
European countries, respectively. However, age-adjusted mortality rates showed a significant
annual decrease of -0.7% in the north of Europe, a moderate rise of 0.7% in the west, and substantial
increases of 1.4% in the south and 2.0% in the east. This trend was similar among women, but with
lower mortality rates. Age-period-cohort models showed three different birth-cohort patterns for
both men and women: a decrease in mortality trend for those generations born after 1920 in the
Nordic countries, a similar but lagged decline for cohorts born after 1930 in western and southern
European countries, and a continuous increase throughout all birth cohorts in eastern Europe.
Similar but more heterogeneous regional patterns were observed for period effects.
Conclusion: Kidney cancer mortality trends in Europe showed a clear north-south pattern, with
high rates on a downward trend in the north, intermediate rates on a more marked rising trend in
the east than in the west, and low rates on an upward trend in the south. The downward pattern
observed for cohorts born after 1920–1930 in northern, western, and southern regions suggests
more favourable trends in coming years, in contrast to the eastern countries where birth-cohort
pattern remains upward.
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Background
Kidney cancer incidence and mortality rates have
increased during the last years in different countries [1-4].
Renal cancer caused 29,546 deaths in men and 16,682 in
women in the European Union in 1998[5], and accounts
for approximately 3% of all malignant tumours[6]. In the
last decades of the 20th century, 5-year relative survival for
renal cancer patients was about 55% in Europe[7] and
60% in the United States[8]. The disease is more frequent
in men and in rural areas[6].
The incorporation of new diagnostic techniques in recent
years, such as echography, computed tomography, and
magnetic resonance imaging, may have had an influence
on the detected rise in incidence[1]. Nevertheless, the
increased use of these imaging procedures does not com-
pletely account for the rising incidence of all stages of kid-
ney cancer[9], and other well-known risk factors, such as
smoking, may also be contributing to the underlying inci-
dence and mortality trends. To explore recent trends in
Europe, this study analysed and compared trends in kid-
ney cancer mortality in different European countries over
the last two decades, quantifying the effect of age, death
period, and birth cohort on the observed trends.
Methods
The number of kidney cancer deaths and the population
estimates for the respective European countries, broken
down by year, sex, and age group, were drawn from the
World Health Organization Mortality Database over the
period 1981–2000. Deaths from kidney cancer corre-
sponded to code 189 of the eighth and ninth revisions of
the International Classification of Diseases[10], and codes
C64- C66, C68 of the tenth revision[11]. Countries of the
former Czechoslovakia, USSR, and Yugoslavia were
excluded from the analysis since data were only available
as a whole during the 1980 decade. Similarly, Germany
was excluded to avoid spurious trends resulting from
merging data of the former Democratic and Federal
Republics prior to 1990. Some countries, such as Belgium,
Poland, Portugal, Romania, and Switzerland, were also
excluded due to incomplete kidney cancer mortality series
during the study period. For the remaining countries,
matrices of kidney cancer deaths and population broken
down by 5-year calendar period and age group (0–4, 5–
9,..., 80–84, and ≥ 85 years) were generated.
Overall age- and period-adjusted mortality rates, as well as
5-year period (1981–1985 to 1996–2000) age-adjusted
rates, were calculated for each country and sex using the
direct method with the European standard population.
Log-linear Poisson models were fitted to obtain the
annual percentage change (APC) in age-adjusted mortal-
ity rates for each country. Under the assumption that the
number of deaths by country, 5-year period, and age
group had a Poisson distribution, estimates and 95% con-
fidence intervals (CIs) of age- and period-adjusted mortal-
ity ratios were computed for each country taking the
average for all European countries as reference.
To further study the existence of regional patterns in kidney
cancer mortality, countries were grouped in four geograph-
ical regions: North (Denmark, Finland, Norway, and Swe-
den), West (Austria, France, Ireland, Netherlands, and
United Kingdom), East (Bulgaria and Hungary), and South
(Greece, Italy, and Spain). With data aggregated by region,
the same methods described above were used to estimate
the APC in age-adjusted mortality rates, as well as the age-
and period-adjusted mortality ratio for each region com-
pared to the southern European countries, this latter region
being taken as reference on registering the lowest rates.
Finally, for each country, log-linear Poisson models were
fitted to study the effect of age, period of death, and birth
cohort. Given the 'non-identifiability' problem (the three
factors age, period, and cohort are linearly dependent), we
used Osmond-Gardner's[12] and Decarli-La Vecchia's[13]
solutions, as well as the evaluation of estimable parame-
ters proposed by Holford[14], such as the degree of curva-
ture in each effect and the sum of period and cohort linear
slopes, also known as the net drift. The Osmond-Gardner
and Decarli-La Vecchia solutions split the net drift into
cohort and period slopes by minimizing the disagreement
in parameter estimates between the full three-factor
model and each of the two-factor models (age period, age
cohort, and period cohort). To graphically display the
individual effects, we applied both solutions, together
with the extreme alternative solutions determined by cur-
vatures and exclusive cohort or period linear effects (that
is, assuming zero period or cohort slope). Age groups
younger than 40 years in men, as well as those younger
than 45 years in women, were excluded from this analysis
due to the limited number of deaths in these age groups
for most countries. The open-ended category of persons
aged 85 years and older was also excluded, so that age-
period-cohort analyses were restricted to ages 40–84 years
in men and 45–84 years in women. We checked for extra-
Poisson dispersion[15], and where this was present,
effects were calculated using a negative binomial distribu-
tion. Significant curvatures in cohort and period effects
were tested by using the null chi-square distribution of the
corresponding likelihood ratio statistics. Specific func-
tions for these analyses were written in R[16].
Results
Mortality rates by country
Table 1 shows age- and period-adjusted male and female
mortality rates for the different countries over the entire
1981–2000 period. In all countries studied, mortality was
higher in men than in women. The male-to-female rateBMC Public Health 2006, 6:119 http://www.biomedcentral.com/1471-2458/6/119
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ratio was smaller in most Nordic countries (1.59 in Den-
mark and 1.72 in Sweden), and greater in the southern
countries (2.63, 2.61, and 2.47 in Italy, Spain, and Greece,
respectively).
Among men, the highest age- and period-adjusted mortal-
ity rates were registered by Hungary, Austria, and the Nor-
dic countries (rate ratio with respect to the average for
European countries of 1.48 in Hungary, 1.39 in Austria,
1.34 in Finland, and 1.32 in Sweden), and the lowest rates
by Bulgaria, Greece, and Spain (rate ratios of 0.51, 0.62,
and 0.69, respectively) (Table 1). However, when country-
specific trends were examined (Table 2), it was the Nordic
countries that registered the most favourable results. The
trend was significantly downward in Denmark, Sweden,
and Austria (APC -1.0%, -0.9%, and -0.5%, respectively)
and borderline but non-significant in Finland and Nor-
way. All the remaining countries displayed significant ris-
ing trends. The highest annual increases were mainly
observed in the southern and eastern European countries
(APC 3.0% in Spain, 2.5% in Bulgaria, 2.1% in Greece,
and 1.9% in Hungary).
For women, the results were similar to those observed
among men. The highest age- and period-adjusted mortal-
ity rates corresponded to the Nordic countries and Austria
(rate ratio with respect to the average for European coun-
tries of 1.82 in Denmark, 1.74 in Sweden, 1.60 in Austria,
and 1.54 in Finland), while the lowest rates were regis-
tered by Bulgaria, Greece, and Spain (rate ratios of 0.54,
0.57, and 0.60, respectively) (Table 1). The Nordic coun-
tries displayed downward trends, that were statistically
significant for Denmark and Sweden (APC -1.4% and -
1.1%, respectively), whereas the most steeply rising trends
were observed in the southern and eastern European
countries (APC 2.4% in Greece, 2.1% in Spain, 1.7% in
Hungary, and 1.5% in Bulgaria) (Table 2).
Mortality rates by geographical region
Analyses by region confirmed a clear north-south pattern.
Compared to men in the southern region, overall age- and
period-adjusted mortality rates were 20% higher in the
eastern region (95% CI 17 to 22%), 25% higher in the
west (95% CI 24 to 27%), and 53% higher in the north
(95% CI 50 to 55%) (Table 3). Regarding trends, age-
adjusted mortality rates showed a significant annual
decrease of -0.7% among men in the north of Europe
(95% CI -0.9 to -0.4%), a moderate rise of 0.7% in the
west (95% CI 0.6 to 0.8%), and substantial increases of
1.4% in the south (95% CI 1.2 to 1.5%) and 2.0% in the
east (95% CI 1.6 to 2.3%) (Table 4). The pattern was sim-
ilar among women (Tables 3 and 4), yet some greater dif-
ferences were observed across regions, with a north-to-
south rate ratio of 2.21 (95% CI 2.17 to 2.26). Annual
increases in south and east regions were slightly lower
Table 1: Age- and period-adjusted kidney cancer mortality rates (per European standard 100,000 population) over the entire 1981–
2000 period by country and sex.
Men Women
Country Rate RR* 95% CI p Rate RR* 95% CI p RR†
North
Denmark 7.62 1.27 1.23 to 1.31 <0.001 4.80 1.82 1.76 to 1.88 <0.001 1.59
Finland 8.04 1.34 1.30 to 1.39 <0.001 4.07 1.54 1.49 to 1.60 <0.001 1.97
Norway 7.16 1.19 1.15 to 1.24 <0.001 3.47 1.32 1.26 to 1.38 <0.001 2.06
Sweden 7.92 1.32 1.29 to 1.35 <0.001 4.59 1.74 1.69 to 1.79 <0.001 1.72
West
Austria 8.32 1.39 1.35 to 1.42 <0.001 4.23 1.60 1.56 to 1.65 <0.001 1.97
France 6.60 1.10 1.09 to 1.11 <0.001 2.64 1.00 0.99 to 1.01 0.957 2.50
Ireland 4.99 0.83 0.79 to 0.88 <0.001 2.38 0.90 0.84 to 0.97 0.004 2.09
Netherla
nds
7.87 1.31 1.29 to 1.34 <0.001 3.91 1.48 1.45 to 1.52 <0.001 2.01
UK 5.63 0.94 0.93 to 0.95 <0.001 2.63 1.00 0.98 to 1.01 0.522 2.14
East
Bulgaria 3.04 0.51 0.49 to 0.53 <0.001 1.43 0.54 0.52 to 0.57 <0.001 2.12
Hungary 8.90 1.48 1.45 to 1.52 <0.001 3.95 1.50 1.46 to 1.54 <0.001 2.25
South
Greece 3.73 0.62 0.60 to 0.64 <0.001 1.51 0.57 0.55 to 0.60 <0.001 2.47
Italy 5.92 0.99 0.98 to 1.00 0.010 2.26 0.85 0.84 to 0.87 <0.001 2.63
Spain 4.14 0.69 0.68 to 0.70 <0.001 1.59 0.60 0.59 to 0.61 <0.001 2.61
* Rate ratio with respect to the average for all European countries.
† Male to female rate ratio.
CI, confidence interval; UK, United Kingdom.BMC Public Health 2006, 6:119 http://www.biomedcentral.com/1471-2458/6/119
Page 4 of 8
(page number not for citation purposes)
(0.9% and 1.6%, respectively) than those registered for
Table 2: Age-adjusted kidney cancer mortality rates (per European standard 100,000 population) in 5-year periods by country and sex.
Mortality rate
Country 1981–1985 1986–1990 1991–1995 1996–2000 APC (%)* 95% CI p
Men
North
Denmark 8.20 7.87 7.37 7.02 -1.0 -1.6 to -0.5 <0.001
Finland 8.10 8.32 7.84 7.91 -0.3 -0.9 to 0.3 0.358
Norway 7.40 7.00 6.97 7.27 0.0 -0.6 to 0.6 0.929
Sweden 8.65 8.24 7.47 7.31 -0.9 -1.3 to -0.5 <0.001
West
Austria 8.20 8.93 8.44 7.73 -0.5 -0.9 to 0.0 0.036
France 6.11 6.80 6.71 6.79 0.6 0.4 to 0.8 <0.001
Ireland 4.23 4.66 5.21 5.86 2.0 1.1 to 3.0 <0.001
Netherlands 7.42 8.05 7.93 8.09 0.4 0.1 to 0.8 0.013
UK 5.16 5.57 5.87 5.93 0.9 0.7 to 1.1 <0.001
East
Bulgaria 2.44 2.93 3.17 3.60 2.5 1.8 to 3.2 <0.001
Hungary 7.30 8.80 9.57 9.94 1.9 1.5 to 2.3 <0.001
South
Greece 3.33 3.39 3.90 4.32 2.1 1.5 to 2.6 <0.001
Italy 5.31 6.18 6.33 5.89 0.6 0.4 to 0.8 <0.001
Spain 3.15 3.84 4.60 4.96 3.0 2.7 to 3.3 <0.001
Women
North
Denmark 5.26 5.42 4.39 4.15 -1.4 -1.9 to -0.8 <0.001
Finlandia 4.17 4.26 4.20 3.67 -0.5 -1.1 to 0.2 0.146
Norway 3.40 3.62 3.35 3.52 0.4 -0.3 to 1.2 0.286
Sweden 5.05 4.91 4.18 4.23 -1.1 -1.6 to -0.7 <0.001
West
Austria 4.48 4.32 4.25 3.86 -0.3 -0.8 to 0.2 0.176
France 2.58 2.68 2.66 2.64 0.5 0.2 to 0.7 <0.001
Ireland 2.20 2.38 2.36 2.60 1.4 0.2 to 2.6 0.023
Netherlands 3.95 3.98 3.96 3.77 -0.2 -0.6 to 0.3 0.469
UK 2.36 2.62 2.84 2.70 1.4 1.2 to 1.6 <0.001
East
Bulgaria 1.26 1.35 1.56 1.56 1.5 0.6 to 2.4 0.001
Hungary 3.42 3.88 4.08 4.43 1.7 1.2 to 2.2 <0.001
South
Greece 1.31 1.41 1.57 1.74 2.4 1.6 to 3.2 <0.001
Italy 2.16 2.35 2.38 2.13 0.2 0.0 to 0.5 0.081
Spain 1.35 1.49 1.71 1.79 2.1 1.7 to 2.5 <0.001
* Average annual percentage change in age-adjusted mortality rates.
CI, confidence interval; UK, United Kingdom.
Table 3: Age- and period-adjusted kidney cancer mortality rates (per European standard 100,000 population) over the entire 1981–
2000 period by geographical region and sex.
Men Women
Region Rate RR* 95% CI p Rate RR* 95% CI p RR†
North 7.76 1.53 1.50 to 1.55 <0.001 4.33 2.21 2.17 to 2.26 <0.001 1.79
West 6.37 1.25 1.24 to 1.27 <0.001 2.85 1.46 1.44 to 1.48 <0.001 2.24
East 6.08 1.20 1.17 to 1.22 <0.001 2.87 1.47 1.43 to 1.51 <0.001 2.12
South 5.08 1 - - 1.95 1 - - 2.60
* Rate ratio with respect to the southern European region.
† Male to female rate ratio.
CI, confidence interval.BMC Public Health 2006, 6:119 http://www.biomedcentral.com/1471-2458/6/119
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men.
Age-period-cohort effect
When age-period-cohort models were fitted to each coun-
try, similar results were obtained under both Osmond-
Gardner and Decarli-La Vecchia solutions, and in those
countries with low net drifts, they also agreed with the
exclusive effects. Among men (Figure 1), three patterns of
evolution were observed for cohort effects: a first group
with the Nordic countries, in which mortality trend was
Table 4: Age-adjusted kidney cancer mortality rates (per European standard 100,000 population) in 5-year periods by geographical 
region and sex.
Mortality rate
Region 1981–1985 1986–1990 1991–1995 1996–2000 APC (%)* 95% CI P
Men
North 8.23 7.97 7.46 7.37 -0.7 -0.9 to -0.4 <0.001
West 5.90 6.47 6.53 6.58 0.7 0.6 to 0.8 <0.001
East 5.00 5.98 6.45 6.90 2.0 1.6 to 2.3 <0.001
South 4.37 5.09 5.48 5.40 1.4 1.2 to 1.5 <0.001
Women
North 4.62 4.65 4.08 3.96 -0.8 -1.1 to -0.5 <0.001
West 2.72 2.87 2.95 2.84 0.7 0.5 to 0.8 <0.001
East 2.51 2.79 2.99 3.20 1.6 1.1 to 2.0 <0.001
South 1.80 1.97 2.07 1.97 0.9 0.7 to 1.1 <0.001
* Average annual percentage change in age-adjusted mortality rates.
CI, confidence interval.
Age, period, and cohort effects on kidney cancer mortality for European men Figure 1
Age, period, and cohort effects on kidney cancer mortality for European men. Age effects are expressed as rates per 1,000,000 
person-years, and period and cohort effects as rate ratios (RR) with respect to their average. Osmond-Gardner (black lines) 
and Decarli-La Vecchia solutions (grey lines) were used to estimate period and cohort effects. The shaded areas are deter-
mined by curvatures and exclusive cohort or period slopes. See Methods for further details.
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flat or slightly upward to cohorts born around 1920 and
downward thereafter (p < 0.001 for curvature in cohort
effect); a second group comprised mainly of western and
southern European countries, in which mortality rose
until cohorts born around 1930, and then began to
decline thereafter (p < 0.001 for cohort curvature); and a
third group with the eastern European countries, in which
mortality increased gradually throughout all birth
cohorts, with no clear evidence of a downward trend for
the youngest generations (p = 0.043 for cohort curvature).
Similar but more heterogeneous regional patterns were
observed for period effects, with a downward trend in the
Nordic countries (p = 0.348 for period curvature) and an
upward trend in the eastern countries (p  = 0.104 for
period curvature). Among women (Figure 2), the shape of
cohort and period effects was in general very similar to
that observed for men. Significant departures from the lin-
ear trend in cohort effects were detected among women in
the Nordic, western, and southern countries (p < 0.001 for
cohort curvatures), but not in the eastern countries (p =
0.914 for cohort curvature).
Discussion
Our results show a significant north-south pattern in kid-
ney cancer mortality during the last two decades, with
higher rates on a downward trend in the northern Euro-
pean countries and lower rates on an upward trend in the
southern countries. Age-period-cohort models also sug-
gest that mortality rates decreased for those cohorts born
after 1920 in the Nordic countries, while the trend began
to decline for younger generations born around 1930 in
the western and southern European countries. For eastern
countries, however, rates appeared to increase continu-
ously throughout all birth cohorts.
Renal cell cancer has two forms of presentation, one
hereditary and the other sporadic[17]. The aetiology is not
completely understood. Besides smoking, which is the
most widely accepted risk factor [18-21], there are other
factors that might be associated with increased risk of kid-
ney cancer. Environmental exposure to uranium has
shown no direct influence on kidney cancer, even though
uranium deposited in the human body was related to
Age, period, and cohort effects on kidney cancer mortality for European women Figure 2
Age, period, and cohort effects on kidney cancer mortality for European women. Age effects are expressed as rates per 
1,000,000 person-years, and period and cohort effects as rate ratios (RR) with respect to their average. Osmond-Gardner 
(black lines) and Decarli-La Vecchia solutions (grey lines) were used to estimate period and cohort effects. The shaded areas 
are determined by curvatures and exclusive cohort or period slopes. See Methods for further details.
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renal toxicity[22]. The role of regular use of analgesics and
diuretics are controversial aspects[3,6,23]. Different stud-
ies have reported an association between development of
kidney cancer and several occupational exposures, such as
work in laundries and printing plants, as well as exposure
to chemical substances, principally liposoluble solvents,
with this association being stronger in women [24-26].
Other risk factors include obesity and hyperten-
sion[18,27-29], as well as certain renal disorders and
chronic haemodialysis[3,6]. A protective effect has been
observed with frequent intake of vegetables in both men
and women[30] and with moderate alcohol consumption
in women[29,31], but no consistent association has been
found with physical activity[32,33].
In this study, kidney cancer mortality trends among Euro-
pean men are substantially similar to those already
described for lung cancer[34,35], in great part attributable
to smoking, the principal known risk factor for both kid-
ney and lung cancers. The different birth-cohort patterns
observed in kidney cancer mortality among European
countries may largely be attributed to the different smok-
ing patterns. In the Nordic countries, the upward trend
becomes inverted with the decline in smoking prevalence,
that was mainly due to higher proportions of never smok-
ers in the younger generations[36]. The levelling off of
kidney cancer mortality rates takes place in a lagged fash-
ion for those countries in the west and south of Europe
that undergo the shift in tobacco consumption at a later
point in time. In the eastern European countries, however,
the mortality trend is upward as a consequence of the
increasing prevalence of smokers in successive birth
cohorts[36].
In addition to the effect of smoking, discussion about this
tumour's evolution tends to focus on whether diagnostic
and therapeutic improvements might contribute to
explain the underlying mortality trend. It has been shown
that the increased use of new imaging diagnostic proce-
dures brings forward the date of diagnosis in many renal
cancer patients, thus increasing the incidence of localized
and presymptomatic tumours that otherwise would have
been diagnosed at more advanced disease stages[1]. This
early detection, together with the modest benefit of
immunotherapy for advanced renal cell cancer[37], have
contributed to improve the overall European 5-year sur-
vival for kidney cancer by about 12% from the 1980 to
1990 decades[7,38]. This improvement in prognosis is
consistent with the initial upward and subsequent down-
ward period effect on kidney cancer mortality displayed
for both sexes in some European countries. Nevertheless,
diagnostic and therapeutic improvements cannot fully
explain the heterogeneity in period effects across Europe.
Other alternative factors, such as the different impact of
public health interventions on smoking cessation, may
also be contributing to the observed regional variation.
Conclusion
In summary, substantial differences in kidney cancer mor-
tality were observed across Europe over the last two dec-
ades of the 20th century, with high rates on a downward
trend in the north, intermediate rates on a more marked
rising trend in the east than in the west, and low rates on
an upward trend in the south. The downward pattern
observed for those cohorts born after 1920–1930 in
northern, western, and southern regions suggests more
favourable trends in coming years, in contrast to the east-
ern countries where birth-cohort pattern remains upward.
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